Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Liver Neoplasms 1Carcinoma, Medullary 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Sorafenib 5Nivolumab 3lenvatinib 2cabozantinib 2Ipilimumab 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1atezolizumab 1adavosertib 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Hepatocellular × cabozantinib × Clear all
NCT01658878 2025-12-24

CheckMate040

Bristol-Myers Squibb

Phase 1/2 Completed
657 enrolled 57 charts 2 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT01908426 2021-05-06

CELESTIAL

Exelixis

Phase 3 Completed
707 enrolled 20 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡